DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3l3g27/general_anxiety) has announced the addition of the "General Anxiety Disorder - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for General Anxiety Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for General Anxiety Disorder and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Edgemont Pharmaceuticals, LLC
- H. Lundbeck A/S
- Pfizer Inc.
- lorazepam ER
- Small Molecule to Modulate Glutamate Receptor for Anxiety Disorders
- vortioxetine hydrobromide
For more information visit http://www.researchandmarkets.com/research/3l3g27/general_anxiety